Roth Capital Downgrades Tonix Pharma (TNXP) to Neutral Citing PTSD Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Brookline Capital Markets Downgrades Tonix Pharma (TNXP) to Hold
July 27, 2018 10:04 AM EDTBrookline Capital Markets downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Hold.
For an analyst ratings summary and ratings history on Tonix Pharma click here. For more ratings news on Tonix Pharma click here.
Shares of Tonix Pharma closed at $3.95 yesterday.
... MoreUPDATE: B.Riley/FBR Downgrades Tonix Pharma (TNXP) to Neutral
July 27, 2018 10:04 AM EDT(Updated - July 30, 2018 9:04 AM EDT)
(updated to add analyst comment)
B.Riley/FBR downgraded Tonix Pharma (NASDAQ: TNXP) from Buy to Neutral with a price target of $1.25 (from $8.00).
Analyst David Buck comments "We downgrade our rating for Tonix Pharmaceuticals Holding... More
Tonix Pharma (TNXP) Halted on LUDP
July 27, 2018 9:59 AM EDTTonix Pharma (NASDAQ: TNXP) Halted on LUDP
... More